Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01025479
Recruitment Status : Completed
First Posted : December 3, 2009
Last Update Posted : June 30, 2010
Sponsor:
Information provided by:
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Condition or disease
Prostate Cancer Osteoporosis

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 829 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Study Start Date : November 2009
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.

Secondary Outcome Measures :
  1. To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Korean prostate cancer patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.
Criteria

Inclusion Criteria:

  • pathologic confirmation of prostate cancer
  • patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria:

  • patients who are hard to be analysed by limitation of chart record according to investigators'discretion
  • patients who already have been registered in this study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025479


Locations
Layout table for location information
Korea, Republic of
Research Site
Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Research Site
Chungju-si, Chungcheongbuk-do, Korea, Republic of
Research Site
Cheonan-si, Chungcheongnam-do, Korea, Republic of
Research Site
Gangneung-si, Gangwon-do, Korea, Republic of
Research Site
Goyang-si, Gyeonggi-do, Korea, Republic of
Research Site
Guri-si, Gyeonggi-do, Korea, Republic of
Research Site
Gumi-si, Gyeongsangbuk-do, Korea, Republic of
Research Site
Gyeongju-si, Gyeongsangbuk-do, Korea, Republic of
Research Site
Masan-si, Gyeongsangnam-do, Korea, Republic of
Research Site
Iksan-si, Jeollabuk-do, Korea, Republic of
Research Site
Daegu, Korea, Republic of
Research Site
Daejeon, Korea, Republic of
Research Site
Gwangju, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Jeju, Korea, Republic of
Research Site
Pusan, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Ulsan, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Joon Woo Bahn, MD AstraZeneca Korea
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: AstraZeneca, AstraZeneca MCMD
ClinicalTrials.gov Identifier: NCT01025479    
Other Study ID Numbers: NIS-OKR-CAS-2009/1
First Posted: December 3, 2009    Key Record Dates
Last Update Posted: June 30, 2010
Last Verified: June 2010
Keywords provided by AstraZeneca:
Osteoporosis
Prostate cancer
LHRH agonist and/or anti-androgen agent
Korean prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Osteoporosis
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Prostatic Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases